Companies: 10,795·Total market cap: $144.5T
Amarin Corporation plc

Amarin Corporation plc

AMRNNASDAQHealthcare● Active
$14.23
+$0.30(+2.15%)
Market Cap$294315874
P/E Ratio
52W High$20.9
52W Low$11.65

Amarin Corporation plc (AMRN) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

amrn · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Amarin Corporation plc (AMRN) measures how much investors pay for each dollar of the company's trailing earnings. AMRN's current PE ratio of N/A is calculated by dividing its stock price of $14.23 by its TTM earnings per share of -$1.62.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2026 est. EPS $-0.04
Based on 1 analyst
EPS (TTM)
-$1.62
TTM · diluted EPS
PEG Ratio
-0.13
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Amarin Corporation plc SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2006 – 2025 · Annual
PE Ratio (TTM)
5Y Avg 172.7x
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Amarin Corporation plc
Amarin Corporation plcYou
AMRN
$294MN/A-$1.62
AC Immune S.A.
AC Immune S.A.
ACIU
$223MN/A-$0.70
Altimmune, Inc.
Altimmune, Inc.
ALT
$240MN/A-$1.00
Alto Neuroscience, Inc.
Alto Neuroscience, Inc.
ANRO
$640MN/A-$2.19
Cellectis S.A.
Cellectis S.A.
CLLS
$298MN/A-$0.67
DBV Technologies S.A.
DBV Technologies S.A.
DBVT
$382MN/A-$1.70
enGene Holdings Inc.
enGene Holdings Inc.
ENGN
$84MN/A-$2.29

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 10 of 20 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-1.87
2024-12-31
FY2024
$-4.00
2023-12-31
FY2023
$-3.00
2022-12-31
FY2022
$-5.27
2021-12-31
FY2021
172.66x$0.39
2020-12-31
FY2020
$-1.00
2019-12-31
FY2019
$-1.32
2018-12-31
FY2018
$-7.84
2017-12-31
FY2017
$-5.01
2016-12-31
FY2016
$-8.20

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Amarin Corporation plc (AMRN) measures how much investors pay for each dollar of the company's trailing earnings. AMRN's current PE ratio of N/A is calculated by dividing its stock price of $14.23 by its TTM earnings per share of -$1.62.

PE Ratio = Stock Price ÷ EPS (TTM)
= $14.23 ÷ -$1.62 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

AMRN pe ratio · 6 questions

AMRN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $14.23 and TTM EPS of -$1.62. Data sourced from Financial Modeling Prep via AMRN's SEC 10-K and 10-Q filings.

AMRN PE ratioWhat is AMRN PE ratioCurrent PE ratio of AMRNAMRN PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Amarin Corporation plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08